SELLAS Life Sciences (SLS) Amortization of Deferred Charges (2022 - 2026)
SELLAS Life Sciences' (SLS) quarterly Amortization of Deferred Charges came in at $153000.0 in Q1 2026, up 4.08% year-on-year from $147000.0 in Q1 2025, and down 0.65% on a QoQ basis from $154000.0 in Q4 2025.
SELLAS Life Sciences (SLS) Amortization of Deferred Charges (2022 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has 5 years of Amortization of Deferred Charges data on file, last reported at $153000.0 in Q1 2026.
- On a quarterly basis, Amortization of Deferred Charges rose 4.08% year-over-year to $153000.0 in Q1 2026; TTM through Mar 2026 was $603000.0, a 5.79% increase from a year earlier, with the FY2025 full-year figure at $597000.0, up 6.42% from the prior year.
- Amortization of Deferred Charges for Q1 2026 stood at $153000.0, down from $154000.0 in the prior quarter.
- Over the last five years, Amortization of Deferred Charges for SLS reached as high as $207000.0 in Q3 2022 and fell as low as $45000.0 in Q1 2022.
- Historically, Amortization of Deferred Charges has averaged $133117.6 across 5 years, with a median of $138000.0 in 2024.
- On a YoY basis, Amortization of Deferred Charges climbed as much as 93.33% in 2023 and fell as far as 41.06% in 2023.
- Year by year, Amortization of Deferred Charges stood at $123000.0 in 2022, then increased by 4.07% to $128000.0 in 2023, then increased by 15.62% to $148000.0 in 2024, then gained by 4.05% to $154000.0 in 2025, then dropped by 0.65% to $153000.0 in 2026.
- Per Business Quant data, the three most recent Amortization of Deferred Charges figures were $153000.0 in Q1 2026, $154000.0 in Q4 2025, and $147000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | SELLAS Life Sciences | 3.23 Mn | 3.23 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 153,000.00 |
| Mar 31, 2026 | 153,000.00 |
| Dec 31, 2025 | 154,000.00 |
| Dec 31, 2025 | 154,000.00 |
| Sep 30, 2025 | 147,000.00 |
| Sep 30, 2025 | 147,000.00 |
| Jun 30, 2025 | 149,000.00 |
| Jun 30, 2025 | 149,000.00 |
| Mar 31, 2025 | 147,000.00 |
| Mar 31, 2025 | 147,000.00 |
| Dec 31, 2024 | 148,000.00 |
| Dec 31, 2024 | 148,000.00 |
| Sep 30, 2024 | 137,000.00 |
| Sep 30, 2024 | 137,000.00 |
| Jun 30, 2024 | 138,000.00 |
| Jun 30, 2024 | 138,000.00 |
| Mar 31, 2024 | 138,000.00 |
| Mar 31, 2024 | 138,000.00 |
| Dec 31, 2023 | 128,000.00 |
| Dec 31, 2023 | 128,000.00 |